Latest news with #Shanghvi
&w=3840&q=100)
Business Standard
5 days ago
- Business
- Business Standard
Sun Pharma lines up $100 mn to commercialise niche products in FY26
Sun Pharmaceutical Industries has lined up a $100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 million. Elaborating on the speciality product segment, Shanghvi said it is now seeking a partner for the future development and commercialisation of MM-II (for osteoarthritis pain) in certain geographies. "This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added. Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted. "We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi said. The drug maker expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal. Sun Pharma reported a total sales of Rs 5,20,41 crore in FY25. "On the guidance of FY26, we expect mid-to-high single-digit consolidated topline growth for FY26," Shanghvi said. The drug firm expects its FY26 R&D spend to be 6-8 per cent of sales for the next year, he added.
Economic Times
5 days ago
- Business
- Economic Times
Sun Pharma lines up USD 100 mn to commercialise niche products this fiscal
Sun Pharmaceutical Industries has lined up a USD 100 million investment to commercialise innovative products in the current fiscal, according to Chairman and Managing Director Dilip Shanghvi. ADVERTISEMENT The Mumbai-based drug major said the capital outlay will help in significantly strengthening the company's speciality (patented products) business for the future. "For the current year, we are looking to invest approximately USD 100 million additionally on the commercialisation of new speciality products," Shanghvi told analysts in a call. The drug major plans to majorly invest in the launch of two products -- Unloxcyt and Leqselvi. Unloxcyt is indicated for the treatment of adults with metastatic cutaneous squamous cell carcinoma, while Leqselvi is for the treatment of adults with severe alopecia areata. In FY25, the company's global speciality sales rose 17.1 per cent to USD 1,216 million. ADVERTISEMENT In the January-March quarter of FY25, the sales were up 8.6 per cent to USD 295 on the speciality product segment, Shanghvi said it is now seeking a partner for the future development and commercialisation of MM-II (for osteoarthritis pain) in certain geographies. ADVERTISEMENT "This change is due to the strategic reassessment of our pipeline. We continue to believe in the potential of the product. Another change is that we are now planning a trial of GL0034 in type 2 diabetes as its first indication," he added. Sun Pharma has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology, he noted. ADVERTISEMENT "We are awaiting approval of that transaction and subsequent closing. Checkpoint has recently received approval from USFDA for Unloxcyt for metastatic or locally advanced cutaneous squamous cell carcinoma and we look forward to leveraging our presence to accelerate patient's access to Unloxcyt," Shangvi drug maker expects mid-to-high single-digit consolidated topline growth in the ongoing fiscal. ADVERTISEMENT Sun Pharma reported a total sales of Rs 5,20,41 crore in FY25. "On the guidance of FY26, we expect mid-to-high single-digit consolidated topline growth for FY26," Shanghvi said. The drug firm expects its FY26 R&D spend to be 6-8 per cent of sales for the next year, he added. (You can now subscribe to our Economic Times WhatsApp channel)
Mint
22-05-2025
- Business
- Mint
Sun Pharma to ramp up growth-boosting specialty portfolio in FY26
Sun Pharmaceutical Industries Ltd will continue to focus on its specialty products in FY26, which contributed to India's largest drugmaker's growth last fiscal. The company plans to invest an additional $100 million on the commercialization of its new specialty product pipeline in the US, chairman and managing director Dilip Shanghvi said in an earnings call on Thursday. The total revenue from operations increased 8% year-on-year to ₹ 12,958.8 crore in the fourth quarter ended March, according to its exchange filing on Thursday. That was below ₹ 13,254 crore average revenue estimated by analysts surveyed by Bloomberg. The company's Ebitda (earnings before interest, taxes, depreciation and amortization) was up 22.4% at ₹ 3,716 crore, and adjusted net profit, excluding exceptional items, was up 4.8% year-on-year at ₹ 2,889 crore in the quarter. Sun Pharma's net profit, however, fell 19% year-on-year to ₹ 2,154 crore in Q4 due to exceptional items, including an impairment on an investment. That missed Bloomberg consensus estimate of ₹ 2,794 crore. For the full year, total revenue from operations rose 8.4% to ₹ 52,578.4 crore in FY25. The drugmaker expects its consolidated revenue to rise in mid-to-high single digits in FY26. Ebitda rose 17.3% in FY25, and its adjusted net profit jumped 19%. The performance was driven by improving market share in India and growth in its global specialty business, the company said. 'The near-term pipeline in global specialty is promising, with products such as Leqselvi and Unloxcyt—the latter through our recently announced Checkpoint acquisition—offering significant improvements in patient care,' Shanghvi said. 'We look forward to specialty becoming an increasingly important part of our business.' Leqselvi, used to treat severe alopecia areata–or hair loss in patches–has received approval for launch in the US, and Sun Pharma received a favourable ruling in a patent lawsuit on the drug in April. The company plans to launch it in the second quarter of this fiscal year, Abhay Gandhi, chief executive officer, North America, told investors during the earnings call. Uloxcyt, used to treat metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC, has also received approval for launch, and the company will share a launch timeline once the acquisition of Checkpoint Therapeutics is completed. 'For the current year, we are looking to invest approximately $100 million additionally on commercialization of new specialty [products],' Shanghvi told investors, adding that 'this investment will enable us to significantly strengthen our specialty business for the future.' The investment will be used for commercializing and promoting its new specialty products to healthcare practitioners as well as patient advocacy groups, the management said. The company also announced some changes in its global specialty clinical pipeline. 'We are now seeking a partner for future development and commercialization of MM2 (drug candidate for pain in osteoarthritis) in certain geographies,' Shanghvi said. Additionally, the company is now planning a phase 2 trial for its drug candidate GL0034 with diabetes as the first indication instead of weight loss.
Mint
22-05-2025
- Business
- Mint
Sun Pharma to ramp up specialty products portfolio in FY26 to drive growth
Sun Pharmaceutical Industries Ltd will continue to focus on its specialty products in FY26, which contributed to India's largest drugmaker's growth last fiscal. The company plans to invest an additional $100 million on the commercialization of its new specialty product pipeline in the US, chairman and managing director Dilip Shanghvi said in an earnings call on Thursday. The total revenue from operations increased 8% year-on-year to ₹ 12,958.8 crore in the fourth quarter ended March, according to its exchange filing on Thursday. That was below ₹ 13,254 crore average revenue estimated by analysts surveyed by Bloomberg. The company's Ebitda (earnings before interest, taxes, depreciation and amortization) was up 22.4% at ₹ 3,716 crore, and adjusted net profit, excluding exceptional items, was up 4.8% year-on-year at ₹ 2,889 crore in the quarter. Sun Pharma's net profit, however, fell 19% year-on-year to ₹ 2,154 crore in Q4 due to exceptional items, including an impairment on an investment. That missed Bloomberg consensus estimate of ₹ 2,794 crore. For the full year, total revenue from operations rose 8.4% to ₹ 52,578.4 crore in FY25. The drugmaker expects its consolidated revenue to rise in mid-to-high single digits in FY26. Ebitda rose 17.3% in FY25, and its adjusted net profit jumped 19%. The performance was driven by improving market share in India and growth in its global specialty business, the company said. 'The near-term pipeline in global specialty is promising, with products such as Leqselvi and Unloxcyt—the latter through our recently announced Checkpoint acquisition—offering significant improvements in patient care,' Shanghvi said. 'We look forward to specialty becoming an increasingly important part of our business.' Leqselvi, used to treat severe alopecia areata–or hair loss in patches–has received approval for launch in the US, and Sun Pharma received a favourable ruling in a patent lawsuit on the drug in April. The company plans to launch it in the second quarter of this fiscal year, Abhay Gandhi, chief executive officer, North America, told investors during the earnings call. Uloxcyt, used to treat metastatic cutaneous squamous cell carcinoma (cSCC) or locally advanced cSCC, has also received approval for launch, and the company will share a launch timeline once the acquisition of Checkpoint Therapeutics is completed. 'For the current year, we are looking to invest approximately $100 million additionally on commercialization of new specialty [products],' Shanghvi told investors, adding that 'this investment will enable us to significantly strengthen our specialty business for the future.' The investment will be used for commercializing and promoting its new specialty products to healthcare practitioners as well as patient advocacy groups, the management said. The company also announced some changes in its global specialty clinical pipeline. 'We are now seeking a partner for future development and commercialization of MM2 (drug candidate for pain in osteoarthritis) in certain geographies,' Shanghvi said. Additionally, the company is now planning a phase 2 trial for its drug candidate GL0034 with diabetes as the first indication instead of weight loss. The overall R&D spend for Q4FY25 was ₹ 811.6 crore or 6.4% of sales. The specialty R&D accounted for 36% of the total R&D spent for the quarter, the company said. Sun Pharma pegged its FY26 R&D spends at 6-8% of its sales.
